Adaptin Bio, Inc.

A cancer diagnosis is one part of clinical trial eligibility. Some studies also look for a specific tumor marker. Adaptin’s published APTN-101 study design specifies EGFRvIII-expressing glioblastoma. Read about the study: bit.ly/4gmpBQ2 $APTN

“Immunotherapy” describes a category of treatments. Some release brakes on immune activity. Others use immune cells as the treatment. Understanding the approach helps put a research headline in context. Explore the science: adaptinbio.com $APTN

A recent UCLA-led glioblastoma study linked higher T-cell density inside tumors with longer survival following dual checkpoint immunotherapy. A finding to investigate further, not evidence about APTN-101. Read the research: bit.ly/4zB2nhm $APTN

This #HealthLiteracyMonth, we covered: 🧬 Tumor heterogeneity 🧠 Why surgery can't reach every cell 🚧 The blood-brain barrier 🚏 How BRiTE is designed to carry therapies 📖 Phase 1, decoded 🔗 How APTN-101 is designed to connect cells Thanks for learning with us.

One end binds a marker on glioblastoma cells. The other binds T cells. That's the idea behind APTN-101, Adaptin Bio's investigational bispecific T-cell engager: one molecule designed to connect an immune cell to a tumor cell.

You'll see "investigational" in a lot of biotech posts, including ours. It means a therapy is being studied in clinical research and is not yet approved by regulators. We're decoding the terms behind early clinical research. $APTN

Some therapies can't get into the brain on their own. So what if they caught a ride? Adaptin Bio's investigational BRiTE platform is designed to use activated T cells to carry T-cell engagers across the blood-brain barrier. $APTN

More than 95% of small-molecule drugs and more than 99% of large-molecule drugs do not cross the blood-brain barrier. That delivery challenge is one of the questions shaping Adaptin Bio's investigational research. #HealthLiteracyMonth $APTN

One tumor can contain cells with different target markers. That’s one aspect of tumor heterogeneity and a challenge shaping Adaptin’s research. For #HealthLiteracyMonth, we’re explaining the science behind the strategy. $APTN

Reaching the brain. Addressing differences among tumor cells. Adaptin Bio President CEO Michael Roberts outlined how these two challenges shape Adaptin’s research into T-cell based delivery and modular tumor targeting. $APTN

A preclinical study asked whether human regulatory T cells could be redirected toward glioblastoma cells with a bispecific antibody. The study reported granzyme-dependent tumor-cell killing in the experimental setting. Publication: bit.ly/4nbs9lr $APTN

What will the APTN-101 Phase 1 study evaluate? Primary objective: safety and maximum tolerated dose. Secondary endpoints: pharmacokinetics and objective response rate. Explore: bit.ly/4gmpBQ2 $APTN

On #WorldCancerResearchDay, Adaptin Bio recognizes the researchers, clinicians and study participants helping move new ideas forward. Our focus is improving therapeutic delivery to the brain and other targeted tissues. Learn more at: adaptinbio.com/

Why is delivering biologics to the brain so difficult? Adaptin Bio CEO Michael Roberts and Duke neuro-oncologist Mustafa Khasraw discuss the challenge and the investigational BRiTE platform on Better Biopharma. Watch to learn more: bit.ly/4rmYSru $APTN

Today at 1:00 p.m. ET: Adaptin Bio Co-Founder and CEO Michael Roberts presents at the Life Sciences Virtual Investor Forum hosted by @RIConferences. Register to access the presentation: bit.ly/4yGQmWT $APTN

Adaptin Bio $APTN Co-Founder and CEO Michael Roberts will present at the Life Sciences Virtual Investor Forum hosted by @RIConferences on Thursday, September 17 at 1:00 p.m. ET. Register to attend: bit.ly/4ivVFU9

Meet Kirit Singh, M.D., Ph.D., Chief Scientific Consultant at Adaptin Bio. His work spans biomedical engineering, immunoengineering and translational research, including research supporting the APTN 101 program in glioblastoma. Meet the team: bit.ly/3YSkKxY $APTN